Search

everythinglearnresearchcommunity

for

Search:↓

Excluding alopecia and mucous membrane components from the CLASI-A score reduces its effectiveness in capturing important disease activity.

DLQI is a reasonable quality-of-life measure for alopecia patients, but more research is needed.

Rehabilitation improved patients' mobility but did not reduce 30-day hospital readmission rates after stem cell transplants.

Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.

CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.

The normalized androgen ratio can help manage conditions with excess androgen activity in women.

Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.

The DLQI is reliable but may not fully capture the impact of skin conditions on quality of life, especially in emotional and psychological areas.

The new tool helps measure the impact of alopecia areata on children's quality of life.

The Arabic Skindex-16 is a reliable and valid way to measure the impact of skin conditions on quality of life in Saudi patients.

The Rotterdam Study investigates diseases in older adults and has produced many research findings.

The EQ-5D-5L tool may not accurately measure the impact of alopecia areata on patients' lives.

Skin disease activity scores can help decide when skin symptoms no longer affect the quality of life in patients with mild dermatomyositis.

The Progressive Loss Risk Scale is a system that shows the long-term risks of hair restoration surgery, which can change based on factors like age and transplant area.

The CLASI is a reliable tool for measuring the severity of cutaneous lupus erythematosus.

The Rotterdam Study updated its design and objectives in 2012, providing insights into various diseases in the elderly, including skin cancer, bone health, liver disease, neurological and psychiatric conditions, and respiratory issues.

4-(Ethoxycarbophenyl) retinamide is much less toxic than other retinoids.

Both ASR I and ASR II are effective scalp reduction techniques, with ASR I creating finer scars and ASR II removing more bald area and reducing stretch-back.

A high neutrophil-to-lymphocyte ratio may predict poor response to hair loss treatment.

People with rheumatoid arthritis have poorer sleep quality than healthy individuals.

Low quality of life and high HSS-29 scores increase risk of losing patients during treatment.

Most patients with alopecia areata see significant hair regrowth within 93 days of starting ritlecitinib treatment.

Higher MPV and CRP levels may indicate more severe alopecia areata.

Patients and clinicians generally agree on eyebrow and eyelash hair loss improvements in severe alopecia areata.

The rs1128977 gene variant may affect cholesterol and body measurements.

5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.